X

Articles

23Jul

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

0 Comments | | Return |

After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.

Read all about it on the Communication page by clicking this link: Communications

Related

FDA Releases Zika Virus (ZIKV) Guidance and Grifols ZIKV Assay Licensed

On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...

Read More >

Seasonal Monitoring for WNV to begin June 1, 2019

Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...

Read More >

October 20th Update on Ortho Conversion

The revised CTS algorithm associated with the Ortho platform is now available for review.  Clie...

Read More >

VP, Scientific Affairs Dr. Marion Lanteri Speaks at Symposium on Alternatives to Donation Deferral

As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...

Read More >

Reminder-Confirmatory Algorithm and Assay Changes Effective September 30, 2019

On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...

Read More >

Assay History List

We have now added a new section called the "Assay History List" to the "At A Gla...

Read More >